{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T18:24:10Z","timestamp":1791483850827,"version":"4.3.4"},"reference-count":35,"publisher":"American Society of Hematology","issue":"7","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2007,10,1]]},"abstract":"<jats:p>Patients with Philadelphia (Ph) chromosome\u2013positive acute lymphoblastic leukemia (ALL) have a rapid disease course and a poor prognosis. Dasatinib, a novel, oral, multitargeted kinase inhibitor of BCR-ABL and SRC family kinases, has previously induced responses in patients with imatinib-resistant or -intolerant Ph-positive ALL. We present the interim results of a phase 2 study designed to further assess the efficacy, safety, and tolerability of dasatinib 140 mg in this patient population (n = 36). With a minimum follow-up of 8 months, treatment with dasatinib resulted in substantial hematologic and cytogenetic response rates. Major hematologic responses were achieved in 42% (15\/36) of patients, 67% of whom remained progression-free. Complete cytogenetic responses were attained by 58% (21\/36) of patients. The presence of BCR-ABL mutations conferring imatinib resistance did not preclude a response to dasatinib. Dasatinib was also tolerable, with 6% (2\/36) of patients discontinuing therapy as a result of study-drug toxicity. Most adverse events (AEs) were grade 1 or 2; febrile neutropenia was the most frequent severe AE, but this and other cytopenias were manageable with dose reduction. Dasatinib represents a safe and effective treatment option and an important therapeutic advance for patients with Ph-positive ALL. This trial was registered at www.clinicaltrials.gov as #CA180015.<\/jats:p>","DOI":"10.1182\/blood-2007-02-073528","type":"journal-article","created":{"date-parts":[[2007,5,11]],"date-time":"2007-05-11T21:11:21Z","timestamp":1178917881000},"page":"2309-2315","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":297,"title":["Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome\u2013positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study"],"prefix":"10.1182","volume":"110","author":[{"given":"Oliver","family":"Ottmann","sequence":"first","affiliation":[{"name":"Medizinische Klinik II, Johann Wolfgang Goethe Universit\u00e4t, Frankfurt, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herv\u00e9","family":"Dombret","sequence":"additional","affiliation":[{"name":"Hospital Saint Louis, Paris Cedex, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Martinelli","sequence":"additional","affiliation":[{"name":"Istituto di Ematologica E Oncologica Medica, Policlinico S Orsola, Bologna, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bengt","family":"Simonsson","sequence":"additional","affiliation":[{"name":"Department of Hematology, University Hospital, Uppsala, Sweden;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francois","family":"Guilhot","sequence":"additional","affiliation":[{"name":"Clinical Research Centre, Centre Hospitalier Universitaire la Mil\u00e9trie, Poitiers, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A.","family":"Larson","sequence":"additional","affiliation":[{"name":"University of Chicago, IL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna","family":"Rege-Cambrin","sequence":"additional","affiliation":[{"name":"Dipartimento di Medicina Interna ii ed Ematologia, Azienda Ospedaliera S. Luigi, Orbassano, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerald","family":"Radich","sequence":"additional","affiliation":[{"name":"Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Hochhaus","sequence":"additional","affiliation":[{"name":"Medizinische Fakult\u00e4t Mannheim, Universit\u00e4t Heidelberg, Mannheim, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Marie","family":"Apanovitch","sequence":"additional","affiliation":[{"name":"Bristol-Myers Squibb, Hopewell, NJ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashwin","family":"Gollerkeri","sequence":"additional","affiliation":[{"name":"Bristol-Myers Squibb, Wallingford, CT; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Coutre","sequence":"additional","affiliation":[{"name":"Stanford University School of Medicine, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111811530876000_B1","doi-asserted-by":"crossref","first-page":"207","DOI":"10.7326\/0003-4819-131-3-199908030-00008","article-title":"Chronic myelogenous leukemia: biology and therapy.","volume":"131","author":"Faderl","year":"1999","journal-title":"Ann Intern Med"},{"key":"2019111811530876000_B2","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1182\/asheducation-2005.1.118","article-title":"Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia.","volume":"2005","author":"Ottmann","journal-title":"Hematology (Am Soc Hematol Educ Program)"},{"key":"2019111811530876000_B3","doi-asserted-by":"crossref","first-page":"4075","DOI":"10.1200\/JCO.2004.10.050","article-title":"Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial.","volume":"22","author":"Thomas","year":"2004","journal-title":"J Clin Oncol"},{"key":"2019111811530876000_B4","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1084\/jem.189.9.1399","article-title":"The P190, P210, and P230 forms of the BCR\/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity.","volume":"189","author":"Li","year":"1999","journal-title":"J Exp Med"},{"key":"2019111811530876000_B5","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/ng1343","article-title":"Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia.","volume":"36","author":"Hu","year":"2004","journal-title":"Nat Genet"},{"key":"2019111811530876000_B6","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1056\/NEJMoa011573","article-title":"Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia.","volume":"346","author":"Kantarjian","year":"2002","journal-title":"N Engl J Med"},{"key":"2019111811530876000_B7","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.","volume":"348","author":"O'Brien","year":"2003","journal-title":"N Engl J Med"},{"key":"2019111811530876000_B8","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1182\/blood-2003-01-0154","article-title":"Early prediction of response in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) treated with imatinib.","volume":"103","author":"Wassmann","year":"2004","journal-title":"Blood"},{"key":"2019111811530876000_B9","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1182\/blood-2001-12-0181","article-title":"A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias.","volume":"100","author":"Ottmann","year":"2002","journal-title":"Blood"},{"key":"2019111811530876000_B10","doi-asserted-by":"crossref","first-page":"4396","DOI":"10.1182\/blood-2003-08-2958","article-title":"Update of the hyper-CVAD and imatinib mesylate regimen in Philadelphia (Ph) positive acute lymphocytic leukemia (ALL).","volume":"103","author":"Thomas","year":"2004","journal-title":"Blood"},{"key":"2019111811530876000_B11","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/sj.leu.2404115","article-title":"High-dose imatinib mesylate combined with vincristine and dexamethasone (DIV regimen) as induction therapy in patients with resistant Philadelphia-positive acute lymphoblastic leukemia and lymphoid blast crisis of chronic myeloid leukemia.","volume":"20","author":"Rea","year":"2006","journal-title":"Leukemia"},{"key":"2019111811530876000_B12","doi-asserted-by":"crossref","first-page":"3449","DOI":"10.1182\/blood-2004-09-3785","article-title":"The effect of first-line imatinib interim therapy on the outcome of allogeneic stem cell transplantation in adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.","volume":"105","author":"Lee","year":"2005","journal-title":"Blood"},{"key":"2019111811530876000_B13","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1200\/JCO.2005.03.2177","article-title":"High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL\u2013positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group.","volume":"24","author":"Yanada","year":"2006","journal-title":"J Clin Oncol"},{"key":"2019111811530876000_B14","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1182\/blood-2005-11-4386","article-title":"Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL).","volume":"108","author":"Wassmann","year":"2006","journal-title":"Blood"},{"key":"2019111811530876000_B15","doi-asserted-by":"crossref","first-page":"34227","DOI":"10.1074\/jbc.M402290200","article-title":"A Bcr\/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2.","volume":"279","author":"Dai","year":"2004","journal-title":"J Biol Chem"},{"key":"2019111811530876000_B16","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1182\/blood.V101.2.690","article-title":"BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571.","volume":"101","author":"Donato","year":"2003","journal-title":"Blood"},{"key":"2019111811530876000_B17","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1535-6108(02)00096-X","article-title":"Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia.","volume":"2","author":"Shah","year":"2002","journal-title":"Cancer Cell"},{"key":"2019111811530876000_B18","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","article-title":"Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification.","volume":"293","author":"Gorre","year":"2001","journal-title":"Science"},{"key":"2019111811530876000_B19","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1038\/sj.leu.2402741","article-title":"Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy.","volume":"16","author":"Hochhaus","year":"2002","journal-title":"Leukemia"},{"key":"2019111811530876000_B20","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/sj.leu.2403257","article-title":"P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate.","volume":"18","author":"Illmer","year":"2004","journal-title":"Leukemia"},{"key":"2019111811530876000_B21","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1182\/blood-2003-12-4276","article-title":"Active transport of imatinib into and out of cells: implications for drug resistance.","volume":"104","author":"Thomas","year":"2004","journal-title":"Blood"},{"key":"2019111811530876000_B22","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1126\/science.1099480","article-title":"Overriding imatinib resistance with a novel ABL kinase inhibitor.","volume":"305","author":"Shah","year":"2004","journal-title":"Science"},{"key":"2019111811530876000_B23","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1158\/0008-5472.CAN-05-0259","article-title":"In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants.","volume":"65","author":"O'Hare","year":"2005","journal-title":"Cancer Res"},{"key":"2019111811530876000_B24","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1124\/jpet.102.045260","article-title":"Distribution of STI-571 to the brain is limited by P-glycoprotein-mediated efflux.","volume":"304","author":"Dai","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"key":"2019111811530876000_B25","doi-asserted-by":"crossref","first-page":"549a","DOI":"10.1182\/blood.V104.11.1988.1988","article-title":"BMS-354825, a dual SRC\/ABL kinase inhibitor, displays potent anti-tumor activity in a model of intracranial CML growth [abstract].","volume":"104","author":"Wild","year":"2004","journal-title":"Blood"},{"key":"2019111811530876000_B26","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa055229","article-title":"Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.","volume":"354","author":"Talpaz","year":"2006","journal-title":"N Engl J Med"},{"key":"2019111811530876000_B27","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1093\/biomet\/26.4.404","article-title":"The use of confidence or fiducial limits illustrated in the case of the binomial.","volume":"26","author":"Clopper","year":"1934","journal-title":"Biometrika"},{"key":"2019111811530876000_B28","doi-asserted-by":"crossref","first-page":"29","DOI":"10.2307\/2530286","article-title":"A confidence interval for the median survival time.","volume":"38","author":"Brookmeyer","year":"1982","journal-title":"Biometrics"},{"key":"2019111811530876000_B29","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1182\/blood-2002-09-2896","article-title":"Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis.","volume":"102","author":"Branford","year":"2003","journal-title":"Blood"},{"key":"2019111811530876000_B30","doi-asserted-by":"crossref","first-page":"160a","DOI":"10.1182\/blood.V104.11.553.553","article-title":"The crystal structure of Abl kinase with BMS-354825, a dual SRC\/ABL kinase inhibitor [abstract].","volume":"104","author":"Tokarski","year":"2004","journal-title":"Blood"},{"key":"2019111811530876000_B31","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0889-8588(05)70204-5","article-title":"Salvage therapy for refractory or relapsed acute lymphocytic leukemia.","volume":"15","author":"Garcia-Manero","year":"2001","journal-title":"Hematol Oncol Clin North Am"},{"key":"2019111811530876000_B32","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1038\/sj.leu.2402770","article-title":"Therapy with imatinib mesylate (Glivec) preceding allogeneic stem cell transplantation (SCT) in relapsed or refractory Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL).","volume":"16","author":"Wassmann","year":"2002","journal-title":"Leukemia"},{"key":"2019111811530876000_B33","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1182\/blood-2006-09-047266","article-title":"Dasatinib induces notable hematologic and cytogenetic responses in chronic phase chronic myeloid leukemia after failure of imatinib therapy.","volume":"109","author":"Hochhaus","year":"2007","journal-title":"Blood"},{"key":"2019111811530876000_B34","doi-asserted-by":"crossref","first-page":"4143","DOI":"10.1182\/blood-2006-09-046839","article-title":"Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukaemia in accelerated phase.","volume":"109","author":"Guilhot","year":"2007","journal-title":"Blood"},{"key":"2019111811530876000_B35","doi-asserted-by":"crossref","first-page":"3207","DOI":"10.1182\/blood-2006-09-046888","article-title":"Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis.","volume":"109","author":"Cortes","year":"2007","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/110\/7\/2309\/484087\/zh801907002309.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/110\/7\/2309\/484087\/zh801907002309.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T11:58:36Z","timestamp":1574078316000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/110\/7\/2309\/103633\/Dasatinib-induces-rapid-hematologic-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,10,1]]},"references-count":35,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2007,10,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2007-02-073528","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,10,1]]}}}